Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - phenylephrine hydrochloride, quantity: 5 mg; paracetamol, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; maize starch; pregelatinised starch; microcrystalline cellulose; povidone; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - for temporary relief from symptoms of colds and flu, including runny nose, nasal congestion, headache and body aches and pains. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - phenylephrine hydrochloride, quantity: 5 mg; paracetamol, quantity: 500 mg; chlorphenamine maleate, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; crospovidone; purified water; microcrystalline cellulose; iron oxide red; maize starch; pregelatinised starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - temporary relief of the following cold & flu symptoms: nasal congestion, sinus pain, runny nose, headache, body aches & pains. reduces fever. the night tablets also provide relief from sneezing and itchy or watery eyes, and assist rest by providing relief from these symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; magnesium stearate; maize starch - temporary relief sleeplessness

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 8 mg - tablet, uncoated - excipient ingredients: erythrosine aluminium lake; lactose monohydrate; magnesium stearate; potato starch; povidone; docusate sodium; colloidal anhydrous silica - for the temporary relief of acute moderate pain in patients over the age of 12 years

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: propylene glycol; magnesium stearate; croscarmellose sodium; dichloromethane; purified talc; microcrystalline cellulose; ethylcellulose; hypromellose; isopropyl alcohol; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 1006.25 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: purified talc; propylene glycol; isopropyl alcohol; hypromellose; ethylcellulose; croscarmellose sodium; dichloromethane; microcrystalline cellulose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - amoxyclav generichealth 500/125 and amoxyclav generichealth 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ibuprofen, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 6000; croscarmellose sodium; purified water; povidone; sodium lauryl sulfate; stearic acid; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; purified talc; hypromellose - for the temporary relief of pain and/or inflammation associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, period pain, sore throat, tennis elbow, arthritis, rheumatic pain and aches and pains associated with colds and flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: mannitol; butylated hydroxyanisole; magnesium stearate; croscarmellose sodium; sodium stearylfumarate; sodium lauryl sulfate; povidone - adults ( greater than or equal to 18 years),primary hypercholesterolaemia,ezetimibe administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia),ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,prevention of cardiovascular disease,ezetimibe, is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),,heterozygous familial hypercholesterolaemia (hefh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone,- patients already treated with a statin and ezetimibe,,homozygous familial hypercholesterolaemia (hofh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: purified talc; iron oxide yellow; maize starch; lactose monohydrate; microcrystalline cellulose; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; hypromellose; triethyl citrate; magnesium stearate; peg-40 hydrogenated castor oil; povidone; sodium starch glycollate type a; colloidal anhydrous silica - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: titanium dioxide; lactose monohydrate; triethyl citrate; purified talc; sodium starch glycollate type a; hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); peg-40 hydrogenated castor oil; magnesium stearate; povidone; maize starch; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.